ClC1C(F)=NC=C(OCCC2OCCO2)C=1.CC(C)([O-])C.[K+].[CH3:23][N:24]1[CH:28]=[CH:27][C:26]([NH:29][C:30]2[C:39]3[C:34](=[CH:35][CH:36]=[C:37](O)[CH:38]=3)[N:33]=[CH:32][N:31]=2)=[N:25]1.[Cl-].[NH4+]>CN(C)C(=O)C>[CH3:23][N:24]1[CH:28]=[CH:27][C:26]([NH:29][C:30]2[C:39]3[C:34](=[CH:35][CH:36]=[CH:37][CH:38]=3)[N:33]=[CH:32][N:31]=2)=[N:25]13-Chloro-5-[2-(1,3-dioxolan-2-yl)ethoxy]-2-fluoropyridine (4.6 g, 18.4 mmol) and potassium tert-butoxide (2.6 g, 23 mmol) were added to an N,N-dimethylacetamide suspension (5 ml) of 4-[(1-methyl-1H-pyrazol-3-yl)amino]quinazolin-6-ol (2.2 g, 9.1 mmol), and reacted at 200° C. for 2 hours, using microwaves. The reaction solution was cooled to room temperature, aqueous saturated ammonium chloride solution was added, and extracted with ethyl acetate. The organic layer was washed with water and saturated saline water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=75:25) to obtain 6-03-chloro-5-{[2-(1,3-dioxolan-2-yl)ethoxy]pyridin-2-yl}oxy)-N-(1-methyl-1H-pyrazol-3-yl)quinazoline-4-amine (3.1 g, yield: 73%) as a yellow solid.